Study on Sirolimus for Polycystic Kidney Disease
Author Information
Author(s): Serra Andreas L, Kistler Andreas D, Poster Diane, Struker Marian, Wüthrich Rudolf P, Weishaupt Dominik, Tschirch Frank
Primary Institution: University Hospital, Zürich, Switzerland
Hypothesis
Can sirolimus effectively retard kidney volume growth in patients with autosomal dominant polycystic kidney disease (ADPKD)?
Conclusion
The study aims to determine if sirolimus can effectively slow down kidney volume growth in patients with ADPKD.
Supporting Evidence
- Sirolimus has shown effectiveness in reducing cyst growth in animal models of polycystic kidney disease.
- The study is the first clinical trial to examine sirolimus in young patients with early manifestations of ADPKD.
- Kidney volume growth is a predictor of renal functional decline in ADPKD patients.
Takeaway
This study is testing if a medicine called sirolimus can help kids and young adults with a kidney disease called ADPKD by stopping their kidneys from getting bigger.
Methodology
This is a single center, randomized controlled, open label trial assessing the effect of sirolimus on kidney volume growth in ADPKD patients.
Potential Biases
Potential bias in patient selection due to the focus on a specific age group and family history.
Limitations
The study is limited to a single center and may not be generalizable to all ADPKD patients.
Participant Demographics
Patients aged 18-40 years with preserved renal function and documented kidney volume growth.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website